Method of producing antihelmithism preparation

专利摘要:
1425810 Combatting helminthic infestation BAYER AG 24 June 1974 [22 June 1973 13 Dec 1973] 27905/74 Heading A5B Helminthic infestation is combatted in a non-human animal by applying a liquid composition comprising D, L or L-2, 3, 5, 6-tetrahydro-6-phenyl-imidazo-(2, 1-b) thiazole (tetramisole and levamisole respectively) or an acid addition salt thereof e.g. a hydrochloride, as an active ingredient and a liquid diluent to the external skin of the animal. The composition may be sprayed or paired onto the animal. The composition may be in the form of a solution, suspension or emulsion containing conventional excipients e.g. propellants. The compositions may also comprise at least one other anthelmintic ingredient.
公开号:SU724077A3
申请号:SU742046507
申请日:1974-06-21
公开日:1980-03-25
发明作者:Петер Шульц Ханс；Феге Герберт
申请人:Байер Аг (Фирма)；
IPC主号:

专利说明:

You are mixed with isopropanrl srrttvs. It is in the ratio 10:10:80. ; It was found that the known protective substance tetramisole in the form of a mixture of its d and i - isomers in the form of a pure C-form (levamisole) sludge in the form of an acid-additive product in the form of a liquid preparation has a positive effect comparable to action with a similar treatment with the introduction of the drug through the mouth or the injection of TetraZole in the form of a liquid preparation exhibits an antihelminthic effect comparable to the effect of the treatment with the introduction through the mouth or injection of the commonly used drug; containing the same active substance, then other anthelmintic agents, for example, ruelen or trichlorfon, when they are administered through the mouth or injected, exhibit a significantly greater activity than when they are poured, 11 people receive the first liquid preparations for applying to the skin in the following way. Tetramisole as a pure yisomer (Levismol) or as an acid-additive compound, for example as hydrochloride, solution of nzt is emulsified or suspended in a suitable, well-tolerated skin of solvents or solvent mixtures, and if necessary, additional adjuvants are added. Suitable solvents are with all organic and inorganic solvents that sufficiently absorb the active substance — tetramisole or tetramisole salt, for example hydrochloride, and provide sufficient absorption of the active substance by the skin without damaging the tissues. . The proposed drugs include liquid preparations that, in addition to non-toxic, inert, pharmaceutically acceptable carriers, contain the active substance tetramisole in the form of pure 2-form (levamisole) or in the form of its mixture d, and E-gisomers, in the form of acid addition salts, for example, hydrochloride or liquid preparations for applying skin in certain pre-treated amounts, the content of the active substance in which corresponds to a specific proportion or multiple dose of a single dose. This dosage may be equal, for example, to 1,2,3 and 4 single doses or 1/2 and 1/3 or 1/4 single doses. Once the dose is contained, it is preferable that the amount of active substance that is applied at one time and usually corresponds to half 1/3 or 1/4 of the daily dose. By non-toxic, inert, pharmaceutically acceptable carriers should be understood solid, semi-solid or liquid diluents, fillers and any kind of auxiliary agents for the preparation of drugs. Preferred pharmaceutical preparations in the form of solutions, suspensions, emulsions and sprayable liquids. Pharmaceutical preparations may contain the active substance tetramisole together with customary carriers, for example, adherents:: marylmethylcellulose, methylcellulose, and other cellulose and starch derivatives, polyacrylates, alginates, gelatins, gum arabic, polyvinylpyrrolidone, polyvinyl alcohol, polyvinylpyrrolide, polyvinyl alcohol, acyl alcohol, acyl alcohol, gelatin, gum arabic, polyvinyl pyrrolidone, polyvinyl alcohol, polyvinyl pyrrolidone, polyvinyl alcohol, acyl alcohol, polyvinyl pyrrolidone, polyvinyl alcohol, glyphine, gum arabic, polyvinyl pyrrolidone, polyvinyl alcohol, polyvinyl pyrrolidone, polyvinyl alcohol, acyl alcohol, polyvinyl pyrrolidone, polyvinyl pyrite, polyvinyl pyrrolide, polyacrylate maleic anhydride, polyethylene glycols, paraffins, oils, waxes, silicone l, colloidal silicic acid, or mixtures of these substances. , In solutions and emulsions, in addition to the active substance tetramisole, conventional carriers may be present, for example, solvents: water, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils, in particular cotton oil, peanut oil, corn oil, olive oil, castor oil and sesame oil, capryl / -caprylic acid triglyceride, isopropyl myristate, oleic oleic acid ester, lactic acid ethyl ester, waxy fatty esters slot, e.g. fat, isolable gland coccyx ducks, glycerol; glycerol formal, tetrahydrofurfuryl alcohol and polyethylene glycols; other suitable solvents are, for example, unbranched and / or branched monohydric and / or NiHoroaTOMoHTH alcohols, aromatic and / or aliphatic hydrocarbons, esters of carboxylic acids, chlorinated hydrocarbons, ketones, for example, acetbium and methyl ethyl ketone, and also these substances, you can use, if you use the text, you can use the text, you can use acetone and methyl ethyl ketone, and you will also use the text, you can use the text, you can use the text, you can use the same text, you can use the same text, you can use the same text, you can use it if you want to use it. , dimethylformamide, N.-methylpyrrolidone, dioxane, 2-dimethyl-4-hydroxymethyl-1,3-dioxolane; surface substances (i.e., emulsifiers, wetting agents, and often substances that promote absorption), for example, anionic substances; sodium lauryl sulphate, fatty alcohol ether sulphates, monoethanolamine, mono / dialkyl polyglycol ether and orthophosphoric acid ester, cationic substances, for example acetyltrimethylammonium chloride; ampholytic substances, for example, di-Na-l-luryl-aryl-3-aryl-3-aryl trimethyl ammonium chloride; non-ionic substances.
for example, polyoxyethylated castor oil, polyoxyethylated MOHOojjeax sorbitan, sorbitan monostearate, ethanol, glycerol monostearate, polyoxyethylene stearate, alkylphenol polyglycol ether.
Sprayed liquids can, along with the active substance, tetramisole, contain common excipients, such as adherents, solvents and emulsifiers (halogenated hydrocarbons being important). In addition, the sprayed liquids may contain conventional gas-stripping agents, for example chlorofluorocarbons or butane.
Suspensions can, along with the active substance tetramisole, contain such usual carriers as liquid diluents, for example water, ethyl alcohol, propylene glycol ,. oils; surfactants such as polyoxyethylene sorbitan ester, glycerol mono stearate; thickeners, for example colloidal silicic acid, methylcellulose, aluminum monostearate, polyacrylic acid derivatives, microcrystalline cellulose.
In order to obtain good results, it has generally been found advisable to apply approximately 1-20 mg of tetrumisol per i kg of weight per day. When using the liquid tetramisole hydrochloride preparation for pouring, it was also advisable to apply approximately from 1 to 20 mg tetramisole hydrochloride per kg of weight per day. For animals, the following doses of tetramisole have proven particularly effective.
Solvent
Isopropanol
Hjo
Isopropanol +
LGVM (10%) Pouring
 LGVM - light hydrotreated spindle oil.
Dose, mg / kg
Animals
in liquid preparations for pouring, the active substance, tetramisole, should preferably be contained in an amount of from about 0.1 to 99.5% and more preferably from about 0.5 to 95% by weight of the total
S mixture. .
In addition to the active substance tetramisole and / or the acid-additive product of it, the above liquid preparations for pouring may also contain other pharmaceuticals.
0 active substances, in particular, substance gva, possessing antihelminthic action. These preparations are obtained by known, conventional methods, for example by mixing the active
5 substances with carrier or carriers. . ..
Example 1, Worms Strongyloides ratti. .
Pediatric animals (rats) that were under experimental conditions:
0 infected with worms strongyloides ratti, at the end of the incubation period, the parasites are subjected to treatment. The active substance is poured in the form of a solution.
The effectiveness of the drug. Determine
5 that, after dissection, the worms remaining in the experimental animal are counted, compared with the control animals, which have not been treated, and the activity is calculated from this
0 (in percent).
Tables 1 and 2 indicate the solvent, the method of application and the minimum doses of the proposed and known (trichlorfon) active substances, which ensure the expulsion of more than 90% of the worms. Table 1
The minimum dose of the active substance, i mg / kg
B is known
25
ineffectual vein discharge at 250
25
Subcutaneously
ineffect 10 but at 250
Method Minimal Effective Solvent
use of the active dose
table 2
I
y-y
1 G
Subcutaneously
...four
Pouring
PRI mme R 2. Worms Nippostrongylus muris.
Experimental animals (rats) that were experimentally infected with Nippo :: trongyIuS muris worms, at the end of the incubation period of the parasites, are subjected to treatment. The active substance is poured in the form of a solution. .
Efficacy of npenapaTia certain
+ Pouring
100 .25. 10 25
ten
after the autopsy, the worms remaining in the experimental animal are counted, compared with the control animals that have not been treated, and from this the activity, in percent, of the comparative effectiveness of the active substances proposed and known (trichlorfon) is calculated in that (5 l 3 and 4.
Table 3
at 250
25
50
Polyethylene glycol - 20 O
Ethyl glycol
Tetrahydrofurfuryl alcohol EXAMPLE 3 .. The larvae of Ascarls suum, Experimental animals (rats), KQTO rye were experimentally infected with Ascaris suum worms, 1-3 days after infection, are subjected to treatment. The active substance is poured in the form of a solution. The effectiveness of the drug is determined by the fact that after opening on the 7th day, the solvent is minimally effective per dose, mg / kg
When tetramisole-HC1 is used as the active substance, dissolved, for example, in polyethylene glycol-200, ethylene glycol, cyclohexanone and isopropanol, the minimum dose is 50 mg / kg (expelling worms is more than 90).
Table 4
Ineffective at 250
50 50
Also
Table 5
Table B shows the rates of absorption of the proposed active substances by the method of pouring (when using the dissolving of these substances on the skin of rats, there was no local intolerance). Infections are counted in the experimental animal of the sheet, compared with control animals that have not been treated, and from this, the activity is calculated, in percent, in Table. 5 d & results of the comparison of the effectiveness of the proposed and known active substances.
tl p and m e p 4, Experience with; pulmonary worms in cattle.
 CIRCULATED CATTLE, WHICH WERE BEEN IN THE EXERCISE: OR: under natural conditions, it is contaminated by worms. Dictyocaulus, is subjected to treatment by pouring a solution of the active substance on the back, or injection under the skin.
Efficiency is determined by
The drug is a method of pri-dose Vyde10 wt.% Le-. vamzola in isopropanol +
PRI me R 5. Experience with worms affecting the gastrointestinal tract in cattle (controlled oinjT with adult worms).
Cattle that have been experimentally infected with Haemonehus, Cooperia and Oesophagostcmum worms are subjected to back-pouring treatment with a solution of the active substance.
Table 6
counting larvae, pulmonary worms secreted from feces before and after treatment. Selection of fewer larvae after treatment means that the worms have been killed or damaged so that they can no longer form the larvae.
In table 7 are given the results of the comparison of the effectiveness of the proposed. and the famous (levamisole) drug.
T a b l and c a 7. mg / kg change
: Litchi J jHci,%
The efficacy of the drug is determined by the fact that after the autopsy, the remaining worms in the experimental animal are counted for worms, compared to control animals that have not been treated, and from this the activity is calculated.
The results of the comparison of the effectiveness of the proposed and known (levamisole) drugs are given in Table 8.
Dose Method
A drug . mg / kg
10 wt.% Levamisole in isopropanol + 10 wt.%
LGVM Pouring
Levamisole
By mouth
Example b. Experience with worms affecting the gastrointestinal tract in cattle (controlled experience with larvae in the developmental stage).
Cattle that were in Experimental conditions infected with Haemonchus, Cooperia and Oesophagostomum worms are subjected to treatment by pouring a solution of active matter on the back or by injecting. Method | Dose, Preparation: mg / kg
10 wt.% Levamisole-in isopropanol + 10 wt.% LGME
PRI me R 7. Experience with worms that affect the gastrointestinal tract, in cattle (selection
itz)
Cattle that were experimentally or in vivo infected with different types of worms affecting the gastrointestinal tract (Cooperia, Osterfagia, TrichoStrongylus, Baccostomum Oesopha- gostomum), at the end of the incubationTable 8
Expulsion of worms in% in relation to groups of control animals that were not treated
100 98 97 99
99
100 100 100 100 100
4,100,100
under the skin. The treatment time is chosen so that the larvae are in the fourth stage of development.
The efficacy of the preparations is determined by the fact that after the dissection, the worms remaining in the experimental animal are counted, compared with the control animals that have not been treated, and their activity is calculated from this (see table 9).
Table 9
JHaemonchus Cooperia Oesophagoi s tomum
.93
94
100
The parasites are treated by pouring a solution of the active substance on their backs.
Efficacy is determined by calculating the amount of worms released from feces before and after treatment. The release of fewer eggs after treatment means that the worms were expelled or damaged so that they can no longer
form its (see table 10). Expulsion of worms in% relative to the group of control animals ,. who have not been treated
15
Example 8, Experience with worms affecting the gastrointestinal tract, in bwec.
Sheep that were experimentally infected with Haemonchus or CoQperia worms, at the end of the parasite incubation period, are subjected to treatment by pouring a solution of the active substance on the back.
Method Dose, mg / kg
10 in her.% Levamisole. in isopropanol
Example 9. The Op | 5yyosh1yosh level of the active substance in the blood.
The determination of the level of the active substance in the blood makes it possible to test the absorption of the active substance tetramisole by pouring, which is simpler than the experiments with worms. The level of Active in the blood of cattle, cattle that received 20 mg of levamisole is determined. . Treatment by pouring (levamisole in various solvents) is compared with oral administration {; % -Th aqueous solution of levamisole) and with subcutaneous administration (10% levamisole in 6.9% aqueous solution of NaC E),
The technique.
The active substance is isolated from the blood by the Holbrock method.
72407716
Table 10
Efficacy is determined by calculating the eggs emitted from the feces before and after the treatment.
The release of fewer eggs after treatment means that the worms have been expelled or damaged so that they no longer form eggs (see Table 11).
Table 11
The selection of eggs in%
Haemonchus cooperia
i
and Skelsa. A colourant analysis is carried out spectrophotometrically by measuring light absorption at a wavelength of 215 mm.
When applied by pouring, it is possible to achieve higher levels of the active substance in the blood than when administered by mouth and subcutaneously. Only two hours after the use of the drug, subcutaneous administration gives higher levels than pouring. High levels of the active substance in the blood, i. Good absorption of the active substance is a prerequisite for its antihelminthic effect. Table 12 shows the results of determining the level of the active substance in the blood of animals after pouring 20 mg / kg of the preparation.
17
10 g of levamieola +10, and isopropanol to obtain a total of 100 MP
10 g of levamieol,-10 g of LGME, and chloroform, to obtain, a total of 100 ml,
10% levamieola + 20% polyoxethylated castor oil + isopropyl myristate
10% levamisole + 7.5% sorbitin monooleate + 10% CHClj + isopropimyristate
10% levamieola + 7.5% lecithin + + 10% CHCPj + isopropyl myristate
10% levamieola + 10% LGME + CHLORINE methylene
10% levamisole + sorbitan monooleate + decalin
10% levamieol + 15% sorbitan monooleate + phthalic acid butyl ester
10% levamieol + 25% dimethyl sulfoxide + iopropanol
10% levamisole in methyl ethyl ketone
10% levamieola + 20% methyl ethyl ketone + eopropyl myristate
10% levamieola + 20% dimethyl sulfoxide + 7.5% polyoxyethylated castor oil + + 8.54% methyl ethyl ketone + + eopropyl myristate
10% levamieola + 7.5% lecithin + 20% CHjCE, + isopropyl myristate
10% levamieola + 7.5% polyoxyethylated castor oil 20% СНдСС5 + eopropyl myristate
10% levamisole + 7.5% polyoxyethylirovnnogo castor oil 10% C-HC E + isopropyl myristate
7i4077
18 . Table 12
0.790,700,59
7-29
0,970,860,71
0,640,720,76
1,261,421,17
1,001,200,96
1,001,890,85
0,671,160,94
0,991,020,88
0,940,290.25

0.770,580.43
2,072,131,65
0.65 0.65 0.49
3
1.75 2.44 1.91
2.11 1.91 1.50
1.45 2.8S 2.60
10% levamisole + 7.5% polyoxyethylated castor oil + 20% SNdSR + iopropyl myristate
 -.
10% levamieola + 7.5% polyoxyethylated castor oil + 30% CHjCBj + isopropyl myristate
5% levamieola -f 7.5% popioxyethylated castor oil + 20% SNDS + isopropyl myristate
5% levamieola + polyoxyethylated castor oil + 30% CH СEj isopropyl myristate
2% suitable solution of levamisole
 The composition is administered by mouth.

权利要求:
Claims (2)
[1]
1. Nepoklonov A. Chemical means of animal protection. Rosselkhoeizdat, M., 1971, p.47-50.
[2]
2. US patent 3364112, cl. 242-270, 1967 (prototype).

类似技术:

---

公开号 | 公开日 | 专利标题

---

SU724077A3|1980-03-25|Method of producing antihelmithism preparation

---

DK175632B1|2004-12-27|Two-phase solvent carrier system

---

EP0202837B1|1989-10-18|Polyene antibiotic emulsion formulation

---

RU2124364C1|1999-01-10|Endoparasiticidic agent

---

CA2364742C|2010-03-23|Anthelmintic composition

---

DK156196B|1989-07-10|METHOD OF PREPARING A TETRAMISOL OR LAVAMISOL PREPARATION PREPARATION

---

JPH0643309B2|1994-06-08|Pesticides for helminthic disease

---

RU2219919C2|2003-12-27|Fungicide composition comprising benzoylphenyl- urea

---

IL96387A|1995-06-29|Pour-on formulations containing antibiotics effective for the control of internal and external parasites of homothermic animals

---

US20040014813A1|2004-01-22|Anthelminthic agents for the prevention of parasitic infections in humans and animals II

---

RU2660353C2|2018-07-05|Method and improved pharmaceutical composition for accelerating the transdermal delivery of a pde-5 inhibitor

---

US8501775B2|2013-08-06|Anthelmintics for preventing parasitic infections in humans and animals

---

RU2038825C1|1995-07-09|Method of treatment of northern fur seal puppies with undinariosis

---

EP1301188B1|2004-10-13|Anthelmintic agents for preventing parasitic infections in humans and animals iii

---

RU2204384C1|2003-05-20|Composition for treating and preventing vertebrates against parasites

---

RU2204383C1|2003-05-20|Method for treating and preventing diseases induced by ticks and gadflies in vertebrates

---

AU2004101082A4|2005-03-03|Anthelmintic compositions

---

AU2004101083A4|2005-03-03|Anthelmintic compositions

---

AU2005201107B8|2008-05-15|Anthelmintic compositions

---

AU2003236405B2|2007-10-25|Anthelmintic Composition

---

AU2004101084A4|2005-03-03|Anthelmintic compositions

---

US20040006136A1|2004-01-08|Anthelmintics for preventing parasitic infections in human and animals

---

NZ192352A|1984-07-06|Injectable flukicidal compositions containing tetramisole derivatives

---

AU2008201426A1|2008-04-24|Anthelmintic compositions

同族专利:

---

公开号 | 公开日

---

NL180633C|1900-01-01|

---

NL180633B|1986-11-03|

---

AU6988474A|1975-12-11|

---

FR2233985A1|1975-01-17|

---

FR2233985B1|1978-12-22|

---

JPS5035342A|1975-04-04|

---

GB1425810A|1976-02-18|

---

DE2331793A1|1975-01-16|

---

JPS596844B2|1984-02-15|

---

DE2331793B2|1979-09-27|

---

ZA744001B|1975-07-30|

---

BR7405115D0|1975-01-07|

---

BE816686A|1974-12-23|

---

US3980791A|1976-09-14|

---

IE39520L|1974-12-22|

---

DE2331793C3|1980-07-03|

---

IE39520B1|1978-10-25|

---

LU70356A1|1975-03-27|

---

NL7408296A|1974-12-24|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US3642809A|1965-10-05|1972-02-15|American Cyanamid Co|Method for producing 2 3 5 6-tetra hydroimidazo-thiazoles|US4070476A|1973-02-23|1978-01-24|Fisons Incorporated|Topical anthelmintic compositions and methods of use|

---

US4336262A|1973-02-23|1982-06-22|Fisons Ltd.|Pour-on veterinary anthelmintic|

---

DE2614841C2|1976-04-06|1987-06-25|Bayer Ag, 5090 Leverkusen, De|

---

JPS52171145U|1976-06-19|1977-12-26|

---

US4147785A|1977-03-18|1979-04-03|Graham J. Dobbie|Method for the treatment of onchocerciasis|

---

US4150141A|1977-06-28|1979-04-17|Johnson & Johnson|Treatment for scabies|

---

US4096271A|1977-08-03|1978-06-20|American Cyanamid Company|Slow release injectable formulations of tetramisole and derivatives in benzyl benzoate|

---

FR2484256B1|1979-06-29|1986-10-24|Roussel Uclaf|METHOD FOR CONTROLLING PEST OF HOT BLOOD ANIMALS|

---

US4278684A|1980-06-17|1981-07-14|Janssen Pharmaceutica N.V.|Non-toxic anthelminthic pour-on composition|

---

DE3029426A1|1980-08-02|1982-03-11|Bayer Ag, 5090 Leverkusen|AGAINST EFFECTIVE POUR-ON FORMULATIONS|

---

US4287176A|1980-10-09|1981-09-01|American Cyanamid Co.|Anthelmintic levamisole and tetramisole gel compositions|

---

GB2095107A|1981-03-24|1982-09-29|Janssen Pharmaceutica Nv|Tetramisole-or levamisole pour-on compositions|

---

US4607050A|1981-10-19|1986-08-19|Wellcome Australia Limited|Method of controlling insects and parasites with an aqueous localized pour-on formulation|

---

NZ202526A|1981-11-27|1985-10-11|Ici Australia Ltd|Endoparasiticidalcompositions containing tetramisole|

---

AT42196T|1982-12-13|1989-05-15|American Cyanamid Co|ATHELMINTHIC GELS AND METHOD FOR THE PRODUCTION THEREOF AT ROOM TEMPERATURE.|

---

AU2314184A|1983-01-10|1984-07-12|Robert Young & Company Limited|Endoparasiticidal composition containing levamisole|

---

GB8304927D0|1983-02-22|1983-03-23|Wellcome Found|Pesticidal formulations|

---

NZ209100A|1983-08-22|1987-01-23|Ici Australia Ltd|Topical compositions for control of endoparasites|

---

EP0147883A3|1983-12-21|1986-12-30|Janssen Pharmaceutica N.V.|Aqueous non-aggressive anthelmintic pour-on formulations|

---

JPS63162530U|1987-04-11|1988-10-24|

---

JPS63162531U|1987-04-11|1988-10-24|

---

JPS63193847U|1987-06-02|1988-12-14|

---

WO1993015716A1|1992-02-11|1993-08-19|Janssen Pharmaceutica N.V.|Levamisole or tetramisole based pour-on formulations|

---

JP2855181B2|1993-12-10|1999-02-10|敏雄 鈴木|Composition and method for preventing pine wilt|

---

DE4443888A1|1994-12-09|1996-06-13|Bayer Ag|Dermally administrable formulations of parasiticides|

---

AR035550A1|1999-06-04|2004-06-16|Nufarm Ltd|BIOCID STABLE COMPOSITIONS|

---

GB0501220D0|2005-01-21|2005-03-02|Norbrook Lab Ltd|Anthelmintic composition|

---

WO2008032671A1|2006-09-12|2008-03-20|Nippon Soda Co., Ltd.|Pest control agent in form of stable suspension|

---

JP5867730B2|2010-06-29|2016-02-24|国立研究開発法人産業技術総合研究所|Halide detection agent, method for detecting the same and detection sensor|

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

DE2331793A|DE2331793C3|1973-06-22|1973-06-22|

---